Novartis’ Mayzent delays time wheelchair dependence by 4 years in secondary progressive multiple sclerosis

September 12, 2019
Research and Development ECTRIMS 2019, Mayzent, Novartis, multiple sclerosis, pharma

Novartis has taken the opportunity at the 2019 Congress of The European Committee for Treatment and Research in Multiple Sclerosis …

stephen_stamp

Former Ergomed CEO appointed as Midatech’s Chief Financial Officer

September 11, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ergomed, midatech

Immunotherapy-focused pharmaceutical company Midatech Pharma has appointed Stephen Stamp as Chief Financial Officer (CFO) with immediate effect. He will be …

--1359709322c31

£200m largest ever genetics project launched to combat deadly diseases

September 11, 2019
Research and Development

In a huge step forward for public health and the UK’s global leadership in genomics, a £200 million project has …

biogen_austria_238

Decade-long data support Biogen’s Tecfidera in relapsing multiple sclerosis

September 11, 2019
Research and Development Biogen, multiple sclerosis, pharma, tecfidera

Biogen has revealed new long-term data for Tecfidera (dimethyl fumarate), reinforcing the benefits of the therapy over a decade-long period …

New aggressive strain of Strep A spreading in UK

September 11, 2019
Research and Development Strep A

A new strain of Streptococcus pyogenes called M1UK that is nine times more aggressive is spreading in the UK as …

opdivo_1_1

BMS unveils strong five-year efficacy data for Opdivo in lung cancer

September 11, 2019
Research and Development Bristol-Myers Squibb, Cancer, immunotherapy, lung cancer, pharma

Bristol-Myers Squibb has unveiled pooled five-year efficacy and safety results for its blockbuster immunotherapy Opdivo (nivolumab) drawn from two Phase …

GlaxoSmithKline acquires Sitari Pharmaceuticals after progress in coeliac disease

September 11, 2019
Research and Development, Sales and Marketing Avalon Ventures, GSK, coeliac disease

Avalon Ventures has announced that it has entered into a definitive agreement with GSK for the acquisition of Sitari Pharmaceuticals …

tony-coles_0

Tony Coles appointed to Pfizer Spinout Cerevel as CEO

September 10, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cerevel, Pfizer, pharma

Cerevel Therapeutics, a pharmaceutical company dedicated to treating neurological diseases, has appointed renowned biotechnology leader Tony Coles as Chief Executive …

gary_gordon

Ayala hires AbbVie’s Gary Gordon as new CMO

September 10, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Ayala

AbbVie’s former Vice President of Oncology has moved to Ayala Pharmaceuticals to work as its new Chief Medical Officer (CMO).  …

Public Health England

Public Health England calls for action against growing UK opioid crisis threat

September 10, 2019
Manufacturing and Production opioid addiction, phe

Public Health England (PHE) have stated that there are far too many people on prescribed drugs that can cause dependence …

merck-keytruda

MSD’s Keytruda approved for first-line lung cancer use on NHS Scotland

September 10, 2019
Manufacturing and Production, Sales and Marketing Cancer, MSD, SMC, Scotland, keytruda, lung cancer, pharma

MSD and lung cancer patients will be celebrating the news that the pharma giant’s immunotherapy Keytruda (pembrolizumab) has been accepted …

boehringer_biberach_germany_copy

Boehringer’s Ofev scores first-of-its-kind FDA approval in rare lung disease

September 10, 2019
Manufacturing and Production, Sales and Marketing Boehringer Ingelheim, FDA, US, lungs, ofev, pharma, rare disease

Boehringer Ingelheim’s Ofev (nintedanib) capsules have now secured marketing authorisation in the US, it has emerged, for the treatment of …

hiv_virus

SMC gives nod for access to new HIV treatment Dovato

September 10, 2019
Manufacturing and Production HIV, SMC

The Scottish Medicines Consortium (SMC) has approved Dovato (dolutegravir/lamivudine) for use on the NHS, allowing treatment of individuals with a …

Axon seeks global partner after positive Phase 2 data for Alzheimer’s vaccine

September 10, 2019
Manufacturing and Production, Sales and Marketing Alzheimer's, Alzheimers, Axon

Axon Neuroscience has announced data from its Phase 2 trial ADAMANT for the first-in-class vaccine AADvac1 to slow the progression …

Novo Nordisk set to launch price cut for insulin drug NovoLog after harsh criticism over prices in the US

September 9, 2019
Sales and Marketing Novo Nordisk, NovoLog, insulin

Danish drug maker Novo Nordisk has said it will offer a generic version of NovoLog (insulin aspart) at a price …

lilly_entrance_web

Lilly’s LOXO-292 shrinks tumours in lung cancer trial

September 9, 2019
Research and Development, Sales and Marketing Cancer, Eli Lilly, lung cancer, pharma

Eli Lilly has announced its experimental cancer drug LOXO-292, acquired in January, shrank tumours in almost 70% of advanced lung …

shutterstock

Age affects efficacy of immunotherapy treatments in breast cancer patients

September 9, 2019
Research and Development, Sales and Marketing Cancer, breast cancer, pharma

Recent clinical trial data has shown that immune checkpoints blockade (ICB) therapy, designed to unleash a patient’s immune system to …

trump-fda

Trump’s FDA: Is the US regulator being steered by the President?

September 9, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing FDA, Trump, US, drug safety, pharma

FDA activity has fallen under Donald Trump, with the number of warning letters issued by the regulator dropping by a …

novartis_side_building

4.5-year data confirms long-term efficacy of Novartis’ Aimovig in episodic migraine

September 9, 2019
Research and Development, Sales and Marketing Aimovig, Novartis, migraine, pharma

Novartis has lifted the curtain on interim data from the 4.5-year mark of a five-year open-label treatment period (OLTP) investigating …

AstraZeneca’s Imfinzi combo tops chemotherapy in treatment-naive advanced lung cancer

September 9, 2019
Sales and Marketing AstraZeneca, Cancer, Imfinzi, lung cancer, pharma

AstraZeneca has unveiled new Phase 3 data for its immunotherapy Imfinzi (durvalumab), showing that it achieved its primary endpoint when …

The Gateway to Local Adoption Series

Latest content